靶向脂代谢逆转头颈鳞癌治疗耐药性的研究进展

doi:10.13591/j.cnki.kqyx.2024.09.011

Abstract

Abstract:

The reprogramming of lipid metabolism is a significant factor influencing various aspects of head and neck squamous cell carcinoma, including its occurrence, development, metastasis, and resistance to radio-chemotherapy. There is a considerable elevation in the expression levels of enzymes and genes related to lipid metabolism in tumor tissues compared to normal tissues. This up-regulation is associated with both treatment resistance and a poor prognosis. This review focuses mainly on alterations in lipid metabolism in head and neck squamous cell carcinoma. It systematically explores the atypical expression and clinical significance of lipid metabolism-related enzymes, evaluates their influence on treatment resistance, elucidates the underlying mechanisms of this resistance, and discusses current and potential targeted therapeutic approaches. The comprehensive analysis comprises four pivotal aspects: de novo lipogenesis, fatty acid oxidation, glycerophospholipids metabolism, and mevalonate and cholesterol synthesis pathways. Feasible strategies, such as the adjustment of dietary structure, the administration of multi-target drugs, and the utilization of combination treatment therapies, are deliberated as potential interventions to modulate lipid metabolism, reverse treatment resistance, and enhance the efficacy of anti-cancer treatments.

Key words: lipid metabolism, head and neck squamous cell carcinoma, treatment resistance, cancer therapy

CLC Number:

R739.8

WANG Pan, LYU Jiong, ZHU Huiyong. Research progress of reversing treatment resistance in head and neck squamous cell carcinoma by targeting lipid metabolism[J]. Stomatology, 2024, 44(9): 705-709.

References 41

[1]	Fasano M, D’Onofrio I, Belfiore MP, et al. Head and neck squamous cell carcinoma in elderly patients: Role of radiotherapy and chemotherapy[J]. Cancers, 2022, 14(3): 472.
[2]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(1): 17-48.
[3]	Yuan ZC, Huang JT, Teh BM, et al. Exploration of a predictive model based on genes associated with fatty acid metabolism and clinical treatment for head and neck squamous cell carcinoma[J]. J Clin Lab Anal, 2022, 36(11): e24722.
[4]	Li LY, Yang Q, Jiang YY, et al. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer[J]. Nat Commun, 2021, 12(1): 4362.
[5]	Tan M, Lin XY, Chen HY, et al. Sterol regulatory element binding transcription factor 1 promotes proliferation and migration in head and neck squamous cell carcinoma[J]. Peer J, 2023, 11: e15203.
[6]	Li K, Zhang CC, Chen L, et al. The role of acetyl-coA carboxylase2 in head and neck squamous cell carcinoma[J]. Peer J, 2019, 7: e7037.
[7]	Göttgens EL, van den Heuvel CN, de Jong MC, et al. ACLY (ATP citrate lyase) mediates radioresistance in head and neck squamous cell carcinomas and is a novel predictive radiotherapy biomarker[J]. Cancers, 2019, 11(12): 1971.
[8]	Kao YC, Lee SW, Lin LC, et al. Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma[J]. Tumour Biol, 2013, 34(2): 759-768.
[9]	Aquino IG, Bastos DC, Cuadra-Zelaya FJM, et al. Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines[J]. Arch Oral Biol, 2020, 113: 104707.
[10]	Chen JY, Zhang F, Ren XS, et al. Targeting fatty acid synthase sensitizes human nasopharyngeal carcinoma cells to radiation via downregulating frizzled class receptor 10[J]. Cancer Biol Med, 2020, 17(3): 740-752.
[11]	Agostini M, Almeida LY, Bastos DC, et al. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas[J]. Mol Cancer Ther, 2014, 13(3): 585-595. doi: 10.1158/1535-7163.MCT-12-1136 pmid: 24362464
[12]	Almeida LY, Moreira FDS, Santos GASD, et al. FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1[J]. Oral Dis, 2023, 29(2): 649-660.
[13]	Jain P, Nattakom M, Holowka D, et al. Runx1 role in epithelial and cancer cell proliferation implicates lipid metabolism and Scd1 and Soat1 activity[J]. Stem Cells, 2018, 36(10): 1603-1616. doi: 10.1002/stem.2868 pmid: 29938858
[14]	Nanjappa V, Renuse S, Sathe GJ, et al. Chronic exposure to chewing tobacco selects for overexpression of stearoyl-CoA desaturase in normal oral keratinocytes[J]. Cancer Biol Ther, 2015, 16(11): 1593-1603. doi: 10.1080/15384047.2015.1078022 pmid: 26391970
[15]	Min JY, Kim DH. Stearoyl-CoA desaturase 1 as a therapeutic biomarker: Focusing on cancer stem cells[J]. Int J Mol Sci, 2023, 24(10): 8951.
[16]	Schminke B, Shomroni O, Salinas G, et al. Prognostic factor identification by screening changes in differentially expressed genes in oral squamous cell carcinoma[J]. Oral Dis, 2023, 29(1): 116-127.
[17]	Tracz-Gaszewska Z, Dobrzyn P. Stearoyl-CoA desaturase 1 as a therapeutic target for thetreatment of cancer[J]. Cancers, 2019, 11(7): 948.
[18]	Luo M, Liu YQ, Zhang H, et al. Overexpression of carnitine palmitoyltransferase 1A promotes mitochondrial fusion and differentiation of glioblastoma stem cells[J]. Lab Invest, 2022, 102(7): 722-730.
[19]	Schlaepfer IR, Joshi M. CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential[J]. Endocrinology, 2020, 161(2): bqz046.
[20]	Chen YX, Zhou YY, Han FW, et al. A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis[J]. Theranostics, 2020, 10(16): 7193-7210. doi: 10.7150/thno.44877 pmid: 32641987
[21]	Du QQ, Tan ZQ, Shi F, et al. PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation[J]. Cancer Sci, 2019, 110(6): 2050-2062.
[22]	Moody L, Xu GB, Chen H, et al. Epigenetic regulation of carnitine palmitoyltransferase 1 (Cpt1a) by high fat diet[J]. Biochim Biophys Acta Gene Regul Mech, 2019, 1862(2): 141-152.
[23]	Tan ZQ, Xiao LB, Tang M, et al. Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy[J]. Theranostics, 2018, 8(9): 2329-2347. doi: 10.7150/thno.21451 pmid: 29721083
[24]	Holubarsch CJF, Rohrbach M, Karrasch M, et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study[J]. Clin Sci, 2007, 113(4): 205-212.
[25]	Fujiwara N, Nakagawa H, Enooku K, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity[J]. Gut, 2018, 67(8): 1493-1504. doi: 10.1136/gutjnl-2017-315193 pmid: 29437870
[26]	Calzada E, Onguka O, Claypool SM. Phosphatidylethanolamine metabolism in health and disease[J]. Int Rev Cell Mol Biol, 2016, 321: 29-88. doi: 10.1016/bs.ircmb.2015.10.001 pmid: 26811286
[27]	Uchiyama Y, Hayasaka T, Masaki N, et al. Imaging mass spectrometry distinguished the cancer and stromal regions of oral squamous cell carcinoma by visualizing phosphatidylcholine (16: 0/16: 1) and phosphatidylcholine (18: 1/20: 4)[J]. Anal Bioanal Chem, 2014, 406(5): 1307-1316.
[28]	Yang XH, Song XW, Yang XD, et al. Big cohort metabolomic profiling of serum for oral squamous cell carcinoma screening and diagnosis[J]. Natural Sciences, 2022, 2(1): e20210071.
[29]	Wang YH, Zhang XX, Wang S, et al. Identification of metabolism-associated biomarkers for early and precise diagnosis of oral squamous cell carcinoma[J]. Biomolecules, 2022, 12(3): 400.
[30]	Yang T, Hui RT, Nouws J, et al. Untargeted metabolomics analysis of esophageal squamous cell cancer progression[J]. J Transl Med, 2022, 20(1): 127.
[31]	Liu F, Wu Y, Liu J, et al. A miR-205-LPCAT1 axis contributes to proliferation and progression in multiple cancers[J]. Biochem Biophys Res Commun, 2020, 527(2): 474-480.
[32]	Shida-Sakazume T, Endo-Sakamoto Y, Unozawa M, et al. Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor[J]. PLoS One, 2015, 10(3): e0120143.
[33]	Zhang HY, Zheng YQ. LPCAT1 is transcriptionally regulated by FOXA1 to promote breast cancer progression and paclitaxel resistance[J]. Oncol Lett, 2023, 25(4): 134.
[34]	Tao MY, Luo J, Gu T, et al. LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12(9): 845.
[35]	Xue LY, Qi HY, Zhang H, et al. Targeting SREBP-2-regulated mevalonate metabolism for cancer therapy[J]. Front Oncol, 2020, 10: 1510. doi: 10.3389/fonc.2020.01510 pmid: 32974183
[36]	Tilija Pun N, Jeong CH. Statin as a potential chemotherapeutic agent: Current updates as a monotherapy, combination therapy, and treatment for anti-cancer drug resistance[J]. Pharmaceuticals, 2021, 14(5): 470.
[37]	Kansal V, Burnham AJ, Kinney BLC, et al. Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models[J]. J Immunother Cancer, 2023, 11(1): e005940.
[38]	Fernandez KA, Allen P, Campbell M, et al. Atorvastatin is associated with reduced cisplatin-induced hearing loss[J]. J Clin Invest, 2021, 131(1): e142616.
[39]	Ricco N, Flor A, Wolfgeher D, et al. Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer[J]. Mol Oncol, 2019, 13(9): 1927-1943. doi: 10.1002/1878-0261.12535 pmid: 31225926
[40]	Zhao XY, Guo B, Sun WJ, et al. Targeting squalene epoxidase confers metabolic vulnerability and overcomes chemoresistance in HNSCC[J]. Adv Sci, 2023, 10(27): e2206878.
[41]	Liu Y, Fang LJ, Liu WX. High SQLE expression and gene amplification correlates with poor prognosis in head and neck squamous cell carcinoma[J]. Cancer Manag Res, 2021, 13: 4709-4723. doi: 10.2147/CMAR.S305719 pmid: 34163246

Research progress of reversing treatment resistance in head and neck squamous cell carcinoma by targeting lipid metabolism

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 41

Related Articles 6

Recommended Articles

Metrics

Comments

[1]	HE Yao, ZHAO Zhenyuan, GAO Teng, LIN Peng, CHEN Yiren, SONG Xiaomeng. The effect of knocking down Sec31A on the malignant phenotype of HNSCC [J]. Stomatology, 2024, 44(7): 487-493.
[2]	CHEN Yiren, ZHAO Zhenyuan, ZHENG Yangyu, ZHANG Wei, SONG Xiaomeng. FBXW7 promotes ferroptosis in head and neck squamous cell carcinoma cells through inhibiting c-Myc/SOX2/SLC7A11 [J]. Stomatology, 2024, 44(6): 426-432.
[3]	WANG Yachen,ZHENG Yang,YANG Yuemei,LIU Jie,SONG Xiaomeng,DING Xu,WU Heming,WU Yunong. Nimotuzumab combined with TPF chemotherapy in head and neck squamous cell carcinoma: A preliminary analysis [J]. Stomatology, 2023, 43(4): 312-316.
[4]	JI Huan, LI Meng, YAO Enhui, ZHONG Yi, ZHANG Yuyao, WU Heming, LI Bin. Study on the expression of LncRNA LINC00958 in head and neck squamous cell carcinoma [J]. Stomatology, 2023, 43(11): 968-974.
[5]	JIANG Feng, HE Yao, ZHU Zaiou, DING Xu, YE Jinhai, WU Yunong, SONG Xiaomeng. Effects of knocking down TULP3 on biological behaviors of head and neck squamous cell carcinoma cells [J]. Stomatology, 2022, 42(6): 494-500.
[6]	. Influences of long non-coding RNA MEG3 on the proliferation and invasion of HNSCC [J]. , 2019, 39(5): 400-403.